Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POUR Luděk ŠVÁCHOVÁ Hana ADAM Zdeněk MIKULKOVÁ Zuzana BUREŠOVÁ Ivana KOVÁŘOVÁ Lucie BÜCHLER Tomáš PENKA Miroslav VORLÍČEK Jiří HÁJEK Roman

Year of publication 2010
Type Article in Periodical
Magazine / Source Neoplasma
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Angiogenesis; cytokines; high-dose chemotherapy; multiple myeloma; therapeutic response
Description Our aim was to establish whether the pretreatment levels of angiogenesis activators and inhibitors can be used to predict clinical responses to treatment that included high-dose chemotherapy with peripheral stem cell support. Patients with complete or very good partial response had higher TSP-1 levels in the bone marrow plasma than the partial or insufficient response subgroups. There were no correlations between the pretreatment levels of VEGF, bFGF, endostatin, or angiostatin and the treatment response. Pretreatment concentrations of HGF and TSP-1 were predictive factors for treatment response. Patients with low angiogenesis rate as determined by the relative HGF and TSP-1 concentrations were more likely to achieve complete or very good partial response after high-dose chemotherapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.